Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.40 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL21825446 | 1.00 | PMP22 (0.50) | PMP22HIF1AADRB2CYP1A2CYP2D6 | |
| SCHEMBL30169480 | 0.92 | ADRB2 (0.44) | PMP22HIF1AADRB2CYP1A2CYP2D6 | |
| SCHEMBL594098 | 0.92 | ADRB2 (0.44) | PMP22HIF1AADRB2CYP1A2CYP2D6 | |
| SCHEMBL30254390 | 0.85 | PMP22 (0.40) | PMP22HIF1AADRB2CYP1A2CYP2D6 | |
| Water SCHEMBL28944323 | 0.84 | PMP22 (0.39) | PMP22HIF1AADRB2CYP1A2CYP2D6 | |
| SCHEMBL4258634 | 0.75 | CYP2D6 (0.47) | PMP22HIF1AADRB2CYP1A2CYP2D6 | |
| SCHEMBL207165 | 0.71 | KDM4E (0.41) | CYP1A2TSHRTDP1LMNAKDM4E | |
| SCHEMBL11278988 | 0.71 | HIF1A (0.40) | PMP22HIF1AADRB2CYP1A2CYP2D6 | |
| Formaldehyde SCHEMBL11236931 | 0.69 | PKM (0.38) | CYP1A2LMNAKDM4ESMN1; SMN2KLF10 | |
| Acetic Acid SCHEMBL9331096 | 0.69 | PKM (0.47) | ADRB2CYP1A2CYP2D6LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115645374-B | Preparation method of salbutamol sulfate tablet | 山东理工职业学院 | 2024-04-26 | — | — | CN | disclosed |
| CN-115645374-A | Preparation method of salbutamol sulfate tablet | 山东理工职业学院 | 2023-01-31 | — | — | CN | disclosed |
| US-8084461-B2 | dispensers containing a mixture of albuterol and ipratropium bromide, used for inducing bronchodialation or providing relief of bronchospasm in in an individual suffering from copd | DEY, L.P. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110247613-A1 | ALBUTEROL AND IPRATROPIUM INHALATION SOLUTION, SYSTEM, KIT AND METHOD FOR RELIEVING SYMPTOMS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | DEY, L.P. | 2011-10-13 | — | — | US | disclosed |
| US-20050207985-A1 | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | DEY LP | 2005-09-22 | — | — | US | disclosed |
| US-20050175544-A1 | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | DEY LP | 2005-08-11 | — | — | US | disclosed |
| US-6632842-B2 | Reducing medication error and enhancing therapeutic compliance of an individual suffering from COPD by providing a single use inhaler | DEY, L.P. | 2003-10-14 | — | — | US | disclosed |
| US-20030140920-A1 | Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma | DEY L.P. (US) | 2003-07-31 | — | — | US | disclosed |
| EP-0460064-A4 | THERAPEUTIC AEROSOL FORMULATIONS | — | 1992-04-01 | — | — | EP | disclosed |
| EP-0460064-A1 | THERAPEUTIC AEROSOL FORMULATIONS | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1990009781-A1 | THERAPEUTIC AEROSOL FORMULATIONS | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1990-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050175544-A1 | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | KIT, IL5, IL33 | ADRB2 4/4885ADRB1 5/4885PMP22 1551/4885 |
| US-20050207985-A1 | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | CHRM3, ADRB2, CHRM5 | ADRB2 2/4885ADRB1 5/4885PMP22 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.